



June 28, 2012

Office of Financial and Insurance Regulation

P.O. Box 30220

Lansing, MI 48909

**RE: Comments on Benchmarking and Essential Health Benefits**

The National Hemophilia Foundation (NHF) and the Hemophilia Foundation of Michigan (HFM) appreciate the opportunity to provide comments on the benchmark plan and benefits being considered as part of Michigan's essential health benefits (EHB). NHF the nation's leading advocacy organization working to ensure that individuals affected by hemophilia and related bleeding disorders have timely access to high quality medical care and services, regardless of financial circumstances or place of residence. HFM is the local chapter advocating on behalf of Michigan residents with bleeding disorders.

Hemophilia and related bleeding disorders are rare, complex genetic conditions for which there are no known cures. Individuals often experience spontaneous and prolonged internal bleeding in the joints and tissues. To effectively manage these disorders, patients often require life-long infusions of clotting factor therapies that replace the missing or deficient blood proteins, thus preventing debilitating and life threatening internal bleeding. While therapies are safer and more effective than ever, they are also more costly than other types of medication. For example, cost of treatment for a person with severe hemophilia can be \$250,000 a year or more. Developing an inhibitor (i.e., an immune response to treatment), complications such as HIV/AIDS, hepatitis and joint diseases, or bleeding as a result of trauma or surgery can increase those costs to over \$1 million.

We commend the Office of Financial and Insurance Regulation (OFIR) for taking the first step in evaluating potential health benefit plans to be considered as the benchmark plan in the Exchange. As the state evaluates which plan to use as the benchmark it is imperative that the unique healthcare needs of those with bleeding disorders are considered. More specifically, we highly encourage OFIR to guarantee the following:



## 1. Access to specialists at federally recognized hemophilia treatment centers (HTCs)

Since 1974, Congress has authorized and funded a national network of HTCs to provide comprehensive, specialized care for individuals with hemophilia and other bleeding disorders. These centers are staffed with healthcare professionals across multiple disciplines including hematologists, physical therapists, nurses, dentists and social workers that work as a team to provide coordinated care for this complex patient population. In addition to disease and case management, HTCs monitor blood safety and offer numerous educational programs for individuals and their families.

Numerous U.S. Centers for Disease Control and Prevention (CDC) studies show that individuals receiving care at HTCs have a 40 percent reduction in morbidity and mortality, despite the fact that more severe patients are seen at an HTC. Moreover, studies show that patients who use HTCs experience fewer long-term complications and hospitalizations, increasing quality of life and reducing total healthcare care costs over a patient's lifetime.<sup>1,2</sup>

**The ACA specifies that entities covered under section 340B(a)(4) of the Public Health Service Act (which includes federally recognized HTCs) be designated as essential community providers. This designation helps ensure that HTCs are included in qualified health plans and that individuals have access to these specialized healthcare providers. We encourage OFIR to consider including all plans to permit access to state and/or regional HTCs meeting these requirements.**

## 2. Access to the full range of FDA approved clotting factor products

Clotting factor therapies are biological products (derived from human blood plasma or using recombinant technology). There are no generic equivalents. Moreover, because of the nature of bleeding disorders, an individual's response and tolerability for a specific product is unique. For these reasons, NHF's Medical and Scientific Advisory Council (MASAC) recommends that individuals have access to the full range available clotting factor products.<sup>3</sup> Limiting access through the use of restrictive drug formularies, such as requiring prior authorization and preferred drug lists, will negatively impact patient care.

---

<sup>1</sup> Soucie JM et al. Mortality among males with hemophilia: relations with source of medical care. *Blood* 2000; 96:437-442.

<sup>2</sup> Soucie JM et al. Home-based factor infusion therapy and hospitalization for bleeding complications among males with hemophilia. *Haemophilia* 2001; 7:198-206.

<sup>3</sup> MASAC Document #132. (2002). Standards and Criteria for the Care of Persons with Congenital Bleeding Disorders. [www.hemophilia.org](http://www.hemophilia.org)



Therefore, benefit designs employing these methods should be avoided and which product an individual uses should be a decision between patient and physician.<sup>4</sup>

### 3. Access to a range of specialty pharmacy providers

Unlike other types of medication typically bought at a retail pharmacy, clotting factor therapies require special handling, shipping and refrigeration. Additionally, patients often require other products (i.e., syringes, saline), nursing services, and intensive education to manage their complex health condition. These requirements are beyond the ability of a traditional retail pharmacy and are only available through specialty pharmacy providers. These providers are specially trained to handle the unique needs of the bleeding disorder community and are expected to adhere to the standards outline by MASAC.<sup>5</sup> Considering the variability of patient needs and provider services, patients need access to a network of pharmacy providers to properly manage their conditions and live longer, healthier lives. We would also encourage that the agency incorporate provider standards for pharmacies that dispense clotting products.

Regardless of which plan is chosen as the benchmark (i.e., small group, state or federal employee), that plan must adequately address the needs of individuals with bleeding disorders. Finally, it's crucial that whatever plan is selected remains affordable for the very people the Exchange was setup to help find affordable coverage.

We thank you for taking the time to review our comments and for giving them your careful consideration. If you have questions, please contact Michelle Rice, Director of Public Policy, at (317) 517-3032 or [mrice@hemophilia.org](mailto:mrice@hemophilia.org); or Ivan Harner, Executive Director, HFM, at (734) 544-0015 328-3730 or [Harner@hfmich.org](mailto:Harner@hfmich.org).

Sincerely,

Michelle Rice  
Director of Public Policy  
National Hemophilia Foundation

Ivan C. Harner, FACHE  
Executive Director  
Hemophilia Foundation of Michigan

<sup>4</sup> MASAC Document #159. (2005). Recommendation Regarding Factor Concentrate Prescriptions and Formulary Development and Restrictions. [www.hemophilia.org](http://www.hemophilia.org).

<sup>5</sup> MASAC Document #188. (2008). Recommendation Regarding Standards of Service for Pharmacy Providers of Clotting Factor Concentrates for Home Use to Patients with Bleeding Disorders. [www.hemophilia.org](http://www.hemophilia.org).